Voltar
Revisão Revisado por pares
BIBTEX RIS

Anthracycline Cardiotoxicity and Its Prevention

1997; Wiley; Volume: 824; Issue: 1 Challenges an Linguagem: Inglês

10.1111/j.1749-6632.1997.tb46225.x

ISSN

1749-6632

Autores

M.G. Mott,

Tópico(s)

Chemotherapy-induced organ toxicity mitigation

Resumo

Annals of the New York Academy of SciencesVolume 824, Issue 1 p. 221-228 Anthracycline Cardiotoxicity and Its Preventiona M. G. MOTT, M. G. MOTT University of Bristol Institute of Child Health Royal Hospital for Sick Children St. Michael's Hill Bristol, BS2 8BJ, United KingdomSearch for more papers by this author M. G. MOTT, M. G. MOTT University of Bristol Institute of Child Health Royal Hospital for Sick Children St. Michael's Hill Bristol, BS2 8BJ, United KingdomSearch for more papers by this author First published: 17 December 2006 https://doi.org/10.1111/j.1749-6632.1997.tb46225.xCitations: 18 a This work, undertaken in Bristol in association with my pediatric cardiology colleagues F. A. Bu'Lock and R. P. Martin, was funded by the Cancer Research Campaign and the CLIC Trust. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Arcamone, F., A. DiMarco, M. Gaetani, et al. 1961. Isolamento ed attivita antitumorle di un antibiotico da Streptomyces sp Giorn. Microbiol 9: 83–90. 2 Dubost, M., P. Ganter, R. Maral, et al. 1963. Un novel antibiotique a proprietes antitumorales: La rubidomycine. CR Acad. Sci. (D) (Paris) 257: 1813–1815. 3 Gilladoga, A. C., C. Manuel, C. Tan, et al. 1976. The cardiotoxicity of adriamycin and daunomycin in children. Cancer 37: 1070–1076. 4 Gottlieb, J. A., E. A. Lefrak, O'Bryan & M. A. Burgess. 1973. Fatal adriamycin cardiomyopathy (CMY): Prevention by dose limitation. Proc. Am. Assoc. Cancer Res. Abstr. 14: 88. 5 Myers, C. E., W. P. McGuire, R. H. Liss, et al. 1997. Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumour response. Science 197: 165–167. 6 Von Hoff, D. D., M. W. Layard, P. Basa, et al. 1979. Risk factors for doxorubicininduced congestive heart failure. Ann. Intern. Med. 91: 701–717. 7 Lipshultz, S. E., S. D. Colan, R. D. Gelber, et al. 1991. Late cardiac effects of adriamycin therapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 324: 808–815. 8 Steinherz, L., P. Steinherz, C. T. C. Tan, G. Heller, & M. L. Murphy 1991. Cardiac toxicity 4–20 years after completing anthracycline therapy. JAMA 226: 1672–1677. 9 Bu'Lock, F. A., M. G. Mott, A. Oakhill & R. P. Martin. 1995. Left ventricular diastolic function after anthracycline chemotherapy in childhood: Relationships with systolic function, symptoms and pathophysiology. Br. Heart J. 73: 340–350. 10 Bu'Lock, F. A., M. G. Mott, A. Oakhill & R. P. Martin. 1996. Early identification of anthracycline cardiomyopathy: Possibilities and implications. Arch. Dis. Child. 75: 1–7. 11 Bu'Lock, F. A., H. M. Gabriel, A. Oakhill, M. G. Mott & R. P. Martin. 1993. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br. Heart J. 70: 185–188. 12 Wexler, Leonard J., Andrich, Mary P., Venzon, David, Berg, Stacey L., Weaver-McClure, Linda, Chen, Clara C., Dilsizian, Vasken, Avila, Nilo, Jarosinski, Paul, Balis, Frank M., Poplack David G. & Horowitz, Marc E. 1996. Randomised trial of the cardioprotective agent ICRF187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. 14(2): 362–372. 13 Lipshultz, Steven E. 1991. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children (Editorial). J. Clin. Oncol. 328–331. 14 Pedersen-Bjergaard, J. 1992. The dioxopiperazine derivatives, their leukemogenic potential and other biological effects. Leuk. Res. 16: 1057–1059. Citing Literature Volume824, Issue1Challenges and Opportunities in Pediatric OncologySeptember 1997Pages 221-228 ReferencesRelatedInformation

Referência(s)